DocWire News Editors

DocwireNews

Final results from the Nordic Lymphoma Group&rsquo;s phase II PHILEMON trial showed that a combination of ibrutinib, lenalidomide, and rituximab is active, well tolerated, and associated with high rates of molecular remission in a high-risk group of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).Findings from this study were presented by Mats Jerkeman, MD, at the Skane University Hospital in Sweden, at the 62nd American Society of Hematology Annual Meeting &amp; Exposition.Patients included in this study had MCL that was R/R to at least one rituximab-containing chemotherapy regimen. The primary endpoint was maximal overall response rate. The investigators also conducted minimal residual disease (MRD) monitoring during the follow-up period.The induction phase of treatment consisted of lenalidomide 15 mg, ibrutinib 560 mg, and rituximab 375 mg/m2 followed by 1,400 mg on select days from cycles one through 11. Patients in complete response (CR), partial response (PR), or stable disease were given treatment during the maintenance phase until progression. The maintenance phase consisted of ibrutinib 560 mg and rituximab 1,400 mg on select days.Across the 50 patients enrolled in the study, the median age was 69.5 years. The median number of previous regimens was two, and four patients had progressed in their disease after single-agent ibrutinib. In 11 out of 49 evaluable patients, the investigators detected a TP53 mutation.The most common treatment-emergent adverse events of any grade included rash (24%) and fatigue (20%). Although five patients developed grade 3/4 neutropenia, hematologic toxicity was generally low grade in severity. There was one death, which the investigators attributed to possible treatment-related toxicity.A total of 27 patients (54%) achieved a CR, and 10 patients (20%) experienced a PR. In evaluable patients with a TP53 mutation, the CR rate was 64%. Additionally, the CR rates among patients with blastoid/pleomorphic histology or Ki67 &gt;30% were 62% and 50%, respectively.The median progression-free survival (PFS) after the median 40-month follow-up period was 18 months (95% confidence interval [CI], 6.5-28). The median overall survival (OS) after follow-up was 47 months (95% CI, 30-64). Among 11 patients with a detectable TP53 mutation at time of relapse, the median PFS was 13 months (95% CI, 4.2-21) versus 34 months (95% CI, 8.3-60) in patients without a TP53 mutation.Approximately 56% of the 28 patients evaluable for MRD at six months experienced molecular remission in blood, whereas 43% of these patients experienced molecular remission in bone marrow. The MRD negativity in bone marrow after 12 months was 68%. A total of two patients with TP53-mutated MCL were MRD-negative in bone marrow after 12 months.According to a Cox regression multivariable analysis, the MCL International Prognostic Index was a significant prognostic indicator for PFS and OS with the ibrutinib, lenalidomide, and rituximab combination regimen.The researchers noted that while &ldquo;the activity in TP53-mutated MCL is lower than in unmutated disease,&rdquo; the combination &ldquo;regimen may still serve as an option for a bridge to an allogeneic transplantation or chimeric antigen receptor T-cell therapy in this category of patients.&rdquo;

MarkAlain Déry, DO

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Ibrutinib, Lenalidomide, Rituximab Combo Shows Durable Activity in R/R MCL

ASH Annual Meeting 2020

Final results from the Nordic Lymphoma Group’s phase II PHILEMON trial showed that a combination of ibrutinib, lenalidomide, and rituximab is active, well tolerated, and ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe